StockMacro
Menu

Amgen

$435.64 +30% in 6 monthsMarket cap $235.6B

AMGN on XNAS, Health Care, Amgen Inc, job postings

Measures activity, not value. Not investment advice.

Profit rose 34% to $9.4B in 12 months as the stock gained 30%, while revenue grew 8.2%.

  • WatchCapital spending up 35% to $587M last quarter, direction unclear
  • BadVisa hiring applications down 8.4%, to 381 from 416 in 12 months

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
31,500
Website
amgen.com
Listed
Nasdaq, US
Last results
3 Nov 2026
Next results
expected around 2 Feb 2027 (an estimate: a year ago it reported on 3 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $10.4B, net income $3.9B.
Quarter to 31 Dec 2021: revenue $6.8B, net income $1.9BQuarter to 31 Dec 2021: revenue $6.8B, net income $1.9BQuarter to 31 Mar 2022: revenue $6.2B, net income $1.5BQuarter to 31 Mar 2022: revenue $6.2B, net income $1.5BQuarter to 30 Jun 2022: revenue $6.6B, net income $1.3BQuarter to 30 Jun 2022: revenue $6.6B, net income $1.3BQuarter to 30 Sep 2022: revenue $6.7B, net income $2.1BQuarter to 30 Sep 2022: revenue $6.7B, net income $2.1BQuarter to 31 Dec 2022: revenue $6.8B, net income $1.6BQuarter to 31 Dec 2022: revenue $6.8B, net income $1.6BQuarter to 31 Mar 2023: revenue $6.1B, net income $2.8BQuarter to 31 Mar 2023: revenue $6.1B, net income $2.8BQuarter to 30 Jun 2023: revenue $7.0B, net income $1.4BQuarter to 30 Jun 2023: revenue $7.0B, net income $1.4BQuarter to 30 Sep 2023: revenue $6.9B, net income $1.7BQuarter to 30 Sep 2023: revenue $6.9B, net income $1.7BQuarter to 31 Dec 2023: revenue $8.2B, net income $767.0MQuarter to 31 Dec 2023: revenue $8.2B, net income $767.0MQuarter to 31 Mar 2024: revenue $7.4B, net income -$113.0MQuarter to 31 Mar 2024: revenue $7.4B, net income -$113.0MQuarter to 30 Jun 2024: revenue $8.4B, net income $746.0MQuarter to 30 Jun 2024: revenue $8.4B, net income $746.0MQuarter to 30 Sep 2024: revenue $8.5B, net income $2.8BQuarter to 30 Sep 2024: revenue $8.5B, net income $2.8BQuarter to 31 Dec 2024: revenue $9.1B, net income $627.0MQuarter to 31 Dec 2024: revenue $9.1B, net income $627.0MQuarter to 31 Mar 2025: revenue $8.1B, net income $1.7BQuarter to 31 Mar 2025: revenue $8.1B, net income $1.7BQuarter to 30 Jun 2025: revenue $9.2B, net income $1.4BQuarter to 30 Jun 2025: revenue $9.2B, net income $1.4BQuarter to 30 Sep 2025: revenue $9.6B, net income $3.2BQuarter to 30 Sep 2025: revenue $9.6B, net income $3.2BQuarter to 31 Dec 2025: revenue $9.9B, net income $1.3BQuarter to 31 Dec 2025: revenue $9.9B, net income $1.3BQuarter to 31 Mar 2026: revenue $8.6B, net income $1.8BQuarter to 31 Mar 2026: revenue $8.6B, net income $1.8BQuarter to 30 Jun 2026: revenue $10.1B, net income $2.4BQuarter to 30 Jun 2026: revenue $10.1B, net income $2.4BQuarter to 30 Sep 2026: revenue $10.4B, net income $3.9BQuarter to 30 Sep 2026: revenue $10.4B, net income $3.9B
31 Dec 2021RevenueNet incomeNet losstallest bar $10.4B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$10.4B$3.9B
30 Jun 2026$10.1B$2.4B
31 Mar 2026$8.6B$1.8B
31 Dec 2025$9.9B$1.3B
30 Sep 2025$9.6B$3.2B
30 Jun 2025$9.2B$1.4B
31 Mar 2025$8.1B$1.7B
31 Dec 2024$9.1B$627.0M
30 Sep 2024$8.5B$2.8B
30 Jun 2024$8.4B$746.0M
31 Mar 2024$7.4B-$113.0M
31 Dec 2023$8.2B$767.0M
30 Sep 2023$6.9B$1.7B
30 Jun 2023$7.0B$1.4B
31 Mar 2023$6.1B$2.8B
31 Dec 2022$6.8B$1.6B
30 Sep 2022$6.7B$2.1B
30 Jun 2022$6.6B$1.3B
31 Mar 2022$6.2B$1.5B
31 Dec 2021$6.8B$1.9B
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $38.9B $36.0B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +8.2% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $9.4B $7.0B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $17.25 $12.94
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 70.9% 66.2% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 32.4% 24.1% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 24.1% 19.5% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 78.4% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $9.6B $11.5B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $13.2B $9.4B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $54.0B $54.6B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $40.8B $45.1B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 3.8 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $26.53
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 25.1 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 6.1 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 7.1 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 16.4 2.0
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 2.2% 1.6%

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
AmgenAMGN (this company) $235.6B25.16.1+8.2%24.1%
Gilead SciencesGILD $206.4Bloss6.7+6.5%-12.5%
ModernaMRNA $78.9Bloss31.2+13%-110%
BiogenBIIB $36.9B1063.6+2.3%3.4%
Revolution MedicinesRVMD $34.9Bloss–––
ExelixisEXEL $15.8B17.86.3+9.1%35.5%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+4.5%

3,228 13F filers vs 3,090

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

81%

439.0M shares held by 13F filers (30 Sep 2026) of 540.9M outstanding (29 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

2.3%

12.6M shares sold short (30 Oct 2026) of 540.9M outstanding (29 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

5.0

12.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-5.9%

13.4M shares sold short in the report before, 12.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

54%

54% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 55%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-8.4%

381 vs 416 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+8.5%

$10.4B vs $9.6B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+35%

$587.0M vs $436.0M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$2.3M

the 12 months before: $0

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$13.3M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

65

65 articles in the last 7 days; its usual week has 8.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

7.6×

65 articles in the last 7 days; its usual week has 8.5.

Price $435.64 on 20 Nov 2026, +30% over 12 months (12-month range $313.85 to $478.48)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $25.7M in the last 12 months (the 12 months before: -$28.6M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 372 published in the last 12 months, -12% on the 12 months before.
Revenue per quarter. Revenue $10.4B in the latest quarter, +8.5% on a year earlier.
Capital spending per quarter. Capital spending $587.0M in the latest quarter, +35% on a year earlier.
Institutional holders (13F filers). 3,228 13F filers reported holding it in the latest 13F quarter, +21% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months, -100% on the 12 months before.
Lobbying spend. Lobbying spend: $13.3M published in the last 12 months, -5.4% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
26 Oct 20268-K and other filingsDirector or officer change
26 Oct 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Oct 2026Lobbying filingnew lobbying registration (BRAVO STRATEGY GROUP)
31 Jul 20268-K and other filingsMaterial cybersecurity incident
12 Jun 2026Lobbying filinglobbying engagement terminated (WASHINGTON ADVOCACY GROUP)
12 Jun 2026Lobbying filingnew lobbying registration (MICHAEL J. LAMOUREUX)
1 Jun 2026Lobbying filingnew lobbying registration (AVENUE SOLUTIONS)
19 May 20268-K and other filingsDirector or officer change
22 Apr 20268-K and other filingsDirector or officer change
22 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Apr 2026Lobbying filinglobbying engagement terminated (TIBER CREEK HEALTH STRATEGIES, INC.)
17 Feb 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 642.0M vs usual 313.0M (2025-12-31); 1.7x the same period a year earlier
30 Jan 20268-K and other filingsA major agreement ended
17 Nov 2025Lobbying filingnew lobbying registration (SIGHTLINE ADVOCACY, LLC)
6 Nov 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 436.0M vs usual 253.0M (2025-09-30); 1.7x the same period a year earlier
9 Sep 2025Sharp changeWikipedia attention spike: wikipedia attention spike, 5,703 vs usual 2,887 (2025-09-01..2025-09-07); 1.8x the same week a year earlier
2 Sep 2025Sharp changeH-1B/E-3 applications change: h-1B/E-3 applications change, 47 vs usual 20 in the same month of earlier years (2025-06-01..2025-06-30); 2.1x the same month a year earlier
7 Aug 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 369.0M vs usual 253.0M (2025-06-30); 1.6x the same period a year earlier
15 Jul 2025Lobbying filingnew lobbying registration (B HALL STRATEGIES, LLC)
13 May 2025Sharp changeShort interest spike: short interest spike, 14.6M vs usual 9.8M (2025-04-30); 1.5x the same period a year earlier
7 May 2025Lobbying filingnew lobbying registration (DAN CRIPPEN)
6 May 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 411.0M vs usual 253.0M (2025-03-31); 1.8x the same period a year earlier
29 Apr 2025Sharp changeShort interest spike: short interest spike, 14.5M vs usual 9.8M (2025-04-15); 1.4x the same period a year earlier
15 Apr 2025Sharp changeShort interest spike: short interest spike, 14.1M vs usual 9.8M (2025-03-31); 1.3x the same period a year earlier
11 Apr 2025Lobbying filingnew lobbying registration (CAPITOL 6 ADVISORS)
1 Apr 2025Sharp changeShort interest spike: short interest spike, 15.1M vs usual 9.8M (2025-03-14); 1.4x the same period a year earlier
18 Mar 2025Sharp changeShort interest spike: short interest spike, 16.2M vs usual 9.8M (2025-02-28); 1.5x the same period a year earlier
4 Mar 2025Sharp changeShort interest spike: short interest spike, 16.1M vs usual 9.8M (2025-02-14); 1.4x the same period a year earlier
20 Oct 2024Lobbying filinglobbying engagement terminated (ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC))
17 Sep 2024Sharp changeWikipedia attention spike: wikipedia attention spike, 5,235 vs usual 3,127 (2024-09-09..2024-09-15); 1.9x the same week a year earlier
19 Jul 2024Lobbying filinglobbying engagement terminated (SONORAN POLICY GROUP, LLC D/B/A STRYK GLOBAL DIPLOMACY, FORMERLY KNOWN AS SONORA)
3 Jun 20248-K and other filingsDirector or officer change
3 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Mar 2024Sharp changeShort interest spike: short interest spike, 11.0M vs usual 7.4M (2024-02-29); 1.5x the same period a year earlier
6 Mar 2024Lobbying filingnew lobbying registration (WASHINGTON ADVOCACY GROUP)
5 Mar 2024Sharp changeShort interest spike: short interest spike, 11.1M vs usual 7.4M (2024-02-15); 1.5x the same period a year earlier
15 Feb 2024Lobbying filingnew lobbying registration (JEFFREY J. KIMBELL & ASSOCIATES, INC.)
13 Feb 2024Lobbying filinglobbying engagement terminated (HAGGERTY POLICY SOLUTIONS)
2 Feb 2024Lobbying filingnew lobbying registration (HILLNORTH LLC)
21 Jan 2024Lobbying filingnew lobbying registration (SONORAN POLICY GROUP, LLC D/B/A STRYK GLOBAL DIPLOMACY, FORMERLY KNOWN AS SONORA)
14 Dec 20238-K and other filingsDirector or officer change
14 Dec 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Nov 2023Sharp changeMany funds opening a new position: many funds opening a new position, 197 vs usual 96.50 (2023-09-30); 2.3x the same period a year earlier
10 Oct 2023Sharp changeFederal obligations jump: federal obligations jump, 205.0M vs usual 21.5M in the same month of earlier years (2023-09-01..2023-09-30); 0.7x the same month a year earlier
6 Oct 20238-K and other filingsCompleted an acquisition or asset sale
12 Sep 2023Sharp changeFederal obligations jump: federal obligations jump, 7.3M vs usual 0 in the same month of earlier years (2023-08-01..2023-08-31)
3 Aug 20238-K and other filingsDirector or officer change
3 Aug 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 May 2023Sharp changeH-1B/E-3 applications change: h-1B/E-3 applications change, 10 vs usual 120 in the same month of earlier years (2023-02-01..2023-02-28); 0.1x the same month a year earlier
9 Mar 20238-K and other filingsA major agreement ended
14 Feb 2023Sharp changeMany funds opening a new position: many funds opening a new position, 151 vs usual 89.50 (2022-12-31); 1.4x the same period a year earlier
11 Oct 2022Sharp changeFederal obligations jump: federal obligations jump, 290.1M vs usual 49K in the same month of earlier years (2022-09-01..2022-09-30); 5905.8x the same month a year earlier
3 Aug 20228-K and other filingsDirector or officer change
3 Aug 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Jun 2022Sharp changeShort interest spike: short interest spike, 18.5M vs usual 11.6M (2022-06-15); 1.8x the same period a year earlier
14 Jun 2022Sharp changeShort interest spike: short interest spike, 20.3M vs usual 11.6M (2022-05-31); 2.0x the same period a year earlier
31 May 2022Sharp changeShort interest spike: short interest spike, 18.9M vs usual 11.5M (2022-05-13); 1.6x the same period a year earlier
17 May 2022Sharp changeShort interest spike: short interest spike, 19.9M vs usual 11.4M (2022-04-29); 1.9x the same period a year earlier
3 May 2022Sharp changeShort interest spike: short interest spike, 20.7M vs usual 11.4M (2022-04-14); 1.9x the same period a year earlier
2 May 2022Lobbying filingnew lobbying registration (HAGGERTY POLICY SOLUTIONS)
12 Apr 2022Sharp changeShort interest spike: short interest spike, 22.5M vs usual 11.4M (2022-03-31); 2.0x the same period a year earlier
5 Apr 2022Sharp changeH-1B/E-3 applications change: h-1B/E-3 applications change, 28 vs usual 11 in the same month of earlier years (2021-11-01..2021-11-30); 3.1x the same month a year earlier
29 Mar 2022Sharp changeShort interest spike: short interest spike, 24.5M vs usual 11.3M (2022-03-15); 2.5x the same period a year earlier
15 Mar 2022Sharp changeShort interest spike: short interest spike, 26.6M vs usual 11.2M (2022-02-28); 3.3x the same period a year earlier
22 Feb 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 287.0M vs usual 169.5M (2021-12-31); 1.7x the same period a year earlier
22 Feb 2022Lobbying filinglobbying engagement terminated (DONNA M. FIORENTINO, LLC)
7 Feb 2022Lobbying filingnew lobbying registration (THE NICKLES GROUP, LLC)
31 Jan 20228-K and other filingsA major agreement ended
19 Jan 2022Lobbying filinglobbying engagement terminated (ADVANCED POLICY CONSULTING, LLC)
19 Jan 2022Lobbying filinglobbying engagement terminated (PUBLIC STRATEGIES WASHINGTON, INC.)
Insider net buying (open market)
Month from 1 May 2022: -$3.4M published
Month from 1 Aug 2022: -$1.7M published
Month from 1 Nov 2022: -$273K published
Month from 1 Aug 2023: -$2.5M published
Month from 1 Nov 2023: -$2.7M published
Month from 1 Dec 2023: -$572K published
Month from 1 May 2024: -$663K published
Month from 1 Feb 2025: -$23.8M published
Month from 1 May 2025: -$280K published
Month from 1 Jun 2025: -$435K published
Month from 1 Aug 2025: -$376K published
Month from 1 Nov 2025: -$3.7M published
Month from 1 Feb 2026: -$376K published
Month from 1 Mar 2026: -$20.8M published
Month from 1 May 2026: -$400K published
Month from 1 Aug 2026: -$4.1M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 79 published
Quarter from 1 Apr 2022: 283 published
Quarter from 1 Jul 2022: 92 published
Quarter from 1 Oct 2022: 81 published
Quarter from 1 Jan 2023: 70 published
Quarter from 1 Apr 2023: 151 published
Quarter from 1 Jul 2023: 210 published
Quarter from 1 Oct 2023: 49 published
Quarter from 1 Jan 2024: 56 published
Quarter from 1 Apr 2024: 233 published
Quarter from 1 Jul 2024: 92 published
Quarter from 1 Oct 2024: 105 published
Quarter from 1 Jan 2025: 57 published
Quarter from 1 Apr 2025: 89 published
Quarter from 1 Jul 2025: 214 published
Quarter from 1 Oct 2025: 65 published
Quarter from 1 Jan 2026: 43 published
Quarter from 1 Apr 2026: 83 published
Quarter from 1 Jul 2026: 181 published
Quarter from 1 Oct 2026: 65 published
Revenue per quarter
Quarter ended 31 Dec 2021: $6.8B; public on 17 Feb 2022
Quarter ended 31 Mar 2022: $6.2B, +5.7% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $6.6B, +1.0% on a year earlier; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $6.7B, -0.8% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Dec 2022: $6.8B, -0.1% on a year earlier; public on 10 Feb 2023
Quarter ended 31 Mar 2023: $6.1B, -2.1% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $7.0B, +5.9% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $6.9B, +3.8% on a year earlier; public on 1 Nov 2023
Quarter ended 31 Dec 2023: $8.2B, +20% on a year earlier; public on 15 Feb 2024
Quarter ended 31 Mar 2024: $7.4B, +22% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $8.4B, +20% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $8.5B, +23% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $9.1B, +11% on a year earlier; public on 15 Feb 2025
Quarter ended 31 Mar 2025: $8.1B, +9.4% on a year earlier; public on 3 May 2025
Quarter ended 30 Jun 2025: $9.2B, +9.4% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $9.6B, +12% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $9.9B, +8.6% on a year earlier; public on 14 Feb 2026
Quarter ended 31 Mar 2026: $8.6B, +5.8% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $10.1B, +9.5% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $10.4B, +8.5% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $287.0M, +66% on a year earlier; public on 17 Feb 2022
Quarter ended 31 Mar 2022: $190.0M, +14% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $246.0M, +33% on a year earlier; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $160.0M, -34% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Dec 2022: $340.0M, +18% on a year earlier; public on 10 Feb 2023
Quarter ended 31 Mar 2023: $344.0M, +81% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $271.0M, +10% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $248.0M, +55% on a year earlier; public on 1 Nov 2023
Quarter ended 31 Dec 2023: $249.0M, -27% on a year earlier; public on 15 Feb 2024
Quarter ended 31 Mar 2024: $230.0M, -33% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $238.0M, -12% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $257.0M, +3.6% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $371.0M, +49% on a year earlier; public on 15 Feb 2025
Quarter ended 31 Mar 2025: $411.0M, +79% on a year earlier; public on 3 May 2025
Quarter ended 30 Jun 2025: $369.0M, +55% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $436.0M, +70% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $642.0M, +73% on a year earlier; public on 14 Feb 2026
Quarter ended 31 Mar 2026: $712.0M, +73% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $513.0M, +39% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $587.0M, +35% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 2,019; public on 14 Feb 2022
31 Mar 2022 report: 2,173; public on 16 May 2022
30 Jun 2022 report: 2,194; public on 15 Aug 2022
30 Sep 2022 report: 2,117; public on 14 Nov 2022
31 Dec 2022 report: 2,274; public on 14 Feb 2023
31 Mar 2023 report: 2,260; public on 15 May 2023
30 Jun 2023 report: 2,187; public on 14 Aug 2023
30 Sep 2023 report: 2,305; public on 14 Nov 2023
31 Dec 2023 report: 2,499; public on 14 Feb 2024
31 Mar 2024 report: 2,563; public on 15 May 2024
30 Jun 2024 report: 2,630; public on 14 Aug 2024
30 Sep 2024 report: 2,660; public on 14 Nov 2024
31 Dec 2024 report: 2,669; public on 14 Feb 2025
31 Mar 2025 report: 2,788; public on 15 May 2025
30 Jun 2025 report: 2,720; public on 14 Aug 2025
30 Sep 2025 report: 2,671; public on 14 Nov 2025
31 Dec 2025 report: 2,936; public on 17 Feb 2026
31 Mar 2026 report: 3,044; public on 15 May 2026
30 Jun 2026 report: 3,090; public on 14 Aug 2026
30 Sep 2026 report: 3,228; public on 16 Nov 2026
Federal obligations
Month from 1 Feb 2022: $2.2M published
Month from 1 Jul 2022: $475K published
Month from 1 Oct 2022: $290.1M published
Month from 1 Dec 2022: $0 published
Month from 1 Mar 2023: $0 published
Month from 1 Aug 2023: $7.3M published
Month from 1 Sep 2023: $205.0M published
Month from 1 Oct 2023: $129K published
Month from 1 May 2024: $0 published
Month from 1 Sep 2025: $2.3M published
Month from 1 Jun 2026: $0 published
Lobbying spend
Quarter from 1 Jan 2022: $2.8M published
Quarter from 1 Apr 2022: $3.1M published
Quarter from 1 Jul 2022: $2.4M published
Quarter from 1 Oct 2022: $3.5M published
Quarter from 1 Jan 2023: $2.5M published
Quarter from 1 Apr 2023: $3.1M published
Quarter from 1 Jul 2023: $2.3M published
Quarter from 1 Oct 2023: $3.3M published
Quarter from 1 Jan 2024: $3.9M published
Quarter from 1 Apr 2024: $3.7M published
Quarter from 1 Jul 2024: $3.1M published
Quarter from 1 Oct 2024: $3.1M published
Quarter from 1 Jan 2025: $3.1M published
Quarter from 1 Apr 2025: $4.0M published
Quarter from 1 Jul 2025: $3.0M published
Quarter from 1 Oct 2025: $4.0M published
Quarter from 1 Jan 2026: $4.0M published
Quarter from 1 Apr 2026: $3.0M published
Quarter from 1 Jul 2026: $2.8M published
Quarter from 1 Oct 2026: $3.5M published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is capital expenditure, quarter at $587.0M (30 Sep 2026), 1.4× its normal quarter; higher than 97% of its own history.
  • Insider net buying (open market): Insiders sold a net $25.7M in the last 12 months (the 12 months before: -$28.6M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 372 published in the last 12 months, -12% on the 12 months before.
  • Revenue per quarter: Revenue $10.4B in the latest quarter, +8.5% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 82 insider trades

No trades in the last 90 days; the latest was filed 13 Aug 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
13 Aug 2026Rachna KhoslaSVP, Business DevelopmentSellafter exercising options3,252$414.06$1.3MForm 4
7 Aug 2026Nancy A. GrygielSVP & CCOSellafter exercising options2,970$402.16$1.2MForm 4
7 Aug 2026Derek MillerSVP, Human ResourcesSellafter exercising options3,890$402.54$1.6MForm 4
5 May 2026Nancy A. GrygielSVP & CCOSell1,237$323.73$400KForm 4
2 Mar 2026Esteban SantosEVP, OperationsSellafter exercising options54,792$379.12$20.8MForm 4
20 Feb 2026Matthew C. BuschVP, Finance & CAOSell1,000$375.79$376KForm 4
21 Nov 2025Nancy A. GrygielSVP & CCOSellafter exercising options3,139$337.26$1.1MForm 4
13 Nov 2025Murdo GordonEVP, Global Commercial OpsSell6,879$336.83$2.3MForm 4

3,228 institutions reported shares at the end of Q3 2026, 81% of the shares outstanding; 226 opened a position, 96 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.48.9M9.05%$20.6B-436K-0.9%
Vanguard Capital Management LLC35.4M6.54%$14.9B+135K+0.4%
State Street Corp31.0M5.72%$13.0B+395K+1.3%
Capital World Investors27.1M5.01%$11.4B-2.0M-6.7%
Invesco Ltd.16.6M3.06%$7.0B+230K+1.4%
Geode Capital Management, LLC16.0M2.97%$6.7B+346K+2.2%
Vanguard Portfolio Management LLC15.1M2.78%$6.3B+201K+1.4%
Charles Schwab Investment Management Inc14.0M2.59%$5.9B-1.0M-7.0%
Morgan Stanley13.6M2.51%$5.7B-103K-0.8%
Wells Fargo & Company6.9M1.28%$2.9B-297K-4.1%

Federal contracts

All 7 federal contracts

No new award in 12 months; the latest was signed 22 Aug 2023. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
22 Aug 2023Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$7.3MNPLATE ADMINISTRATION KIT DEVELOPMENT FOR THE TREATMENT OF APPROVED INDICATIONS, INCLUDING ACUTE RADIATION SYNDROME (ARS)USAspending
28 Sep 2022Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$494.9Mup to $1.1BTREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN.USAspending
26 Sep 2019Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$21.5Mup to $33.3MTHIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TOUSAspending
13 Sep 2018Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$154.4Mup to $154.4MIGF::OT::IGF RTOR NUMBER: RTOR-CSF-0005 ACQUISITION OF COLONY STIMULATING FACTOR(S) (G-CSF OR GM-CSF) FOR MITIGATION OF NEUTROPENIA ARISING FROM EXPOSURE TO IONIZING RADIATIONUSAspending
30 Sep 2016Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and ResponseIGF::OT::IGF FOR OTHER FUNCTIONS PROJECT: ACQUISITION OF COLONY STIMULATING FACTOR(S) (G-CSF OR GM-CSF) FOR MITIGATION OF NEUTROPENIA ARISING FROM EXPOSURE TO IONIZING RADIATION (RTOR-CSF-0003)USAspending
25 Sep 2013Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and ResponseIGF::OT::IGF TASK ORDER 1 UNDER RFP-12-100-SOL-00016USAspending
30 Sep 2009Department of Veterans AffairsMEDICINE REQUIRED FOR CLINICAL TRIAL 551 FOR THE CSPUSAspending

Company events

All 56 company events

In 12 months: 3 director or officer changes, 1 agreement ended, 1 major agreement, 1 cybersecurity incident. Results releases and routine reports are left out.

FiledWhat happenedSource
26 Oct 2026Director or officer change8-K
31 Jul 2026Material cybersecurity incident8-K
19 May 2026Director or officer change8-K
22 Apr 2026Director or officer change8-K
19 Feb 2026Signed a major agreement8-K
30 Jan 2026A major agreement ended8-K
3 Jun 2024Director or officer changeSame filing: shareholder vote results8-K
14 Dec 2023Director or officer change8-K

Reported lobbying spend: $3.5M in Q3 2026, $2.8M in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Jul 2026NewBravo Strategy Groupfor AmgenBiologics, biotechnology policies.MEDFiling
12 Jun 2026EndedWashington Advocacy Groupfor Amgen Inc.Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interestsHealth issuesFiling
12 Jun 2026NewMichael J. Lamoureuxfor Amgen Inc.Educating members on issues affecting Amgen and patientsMEDFiling
1 Apr 2026NewAvenue Solutionsfor Amgen, Inc.Issues related to drug pricing and reimbursement for prescription drugs.Medicare/MedicaidFiling
1 Jan 2026EndedTiber Creek Health Strategies, Inc.for Amgen, Inc.Not statedFiling
1 Oct 2025NewSightline Advocacy, LLCfor AmgenIssues related to the pharmaceutical industryHealth issuesFiling
1 May 2025NewDan Crippenfor Amgenpharmacy pricing, R&D, chronic diseasePharmacyFiling
4 Apr 2025NewCapitol 6 Advisorsfor AmgenFiscal Year 2026, Labor, Health and Human Services and Education Appropriations Act.Health issuesFiling

The 5 newest of 623 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

2 Sep 2025confirmed

Confirmed across sources Attention and Hiring and Filings + Financials

Amgen (AMGN): spent $369.0M on capital projects in the quarter ended 30 Jun 2025, 1.6× the same quarter last year; it also had 47 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year; and it drew 5,703 Wikipedia page views in the week of 1 Sep 2025, 1.8× the same week last year. Three unrelated kinds of activity within 33 days.

  • Financials: Quarterly capital spending jump, became public on 7 Aug 2025
  • Hiring: H-1B/E-3 applications change, became public on 31 Aug 2025
  • Attention: Wikipedia attention spike, became public on 9 Sep 2025
2023-06-30: $271.0M2023-09-30: $248.0M2023-12-31: $249.0M2024-03-31: $230.0M2024-06-30: $238.0M2024-09-30: $257.0M2024-12-31: $371.0M2025-03-31: $411.0M2025-06-30: $369.0M
The quarter ended 30 Jun 2025 against the 8 quarters before it. this quarterearliernormal: $253.0M
See the evidence (3 changes)

Financials: Quarterly capital spending jump became public on 7 Aug 2025

Amgen spent $369.0M on capital projects in the quarter ended 30 Jun 2025, 1.6× the same quarter last year.

This period
$369.0M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$253.0M
Typical spread (median absolute deviation)
$16.5M
How far from its usual level
+4.6
Same quarter last year
$238.0M
History used
3,378 days
2023-06-30: $271.0M2023-09-30: $248.0M2023-12-31: $249.0M2024-03-31: $230.0M2024-06-30: $238.0M2024-09-30: $257.0M2024-12-31: $371.0M2025-03-31: $411.0M2025-06-30: $369.0M
the quarter ended 30 Jun 20258 earlier quartersnormal: $253.0M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Hiring: H-1B/E-3 applications change became public on 31 Aug 2025

Amgen had 47 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year.

This period
47 (June 2025)
Normal month (median of 5 earlier)
20
Typical spread (median absolute deviation)
2
How far from its usual level
+9.0
Same month last year
22
History used
2,099 days
2020-06-01: 72021-06-01: 252022-06-01: 192023-06-01: 202024-06-01: 222025-06-01: 47
June 20255 earlier monthsnormal: 20

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

Check it at the source: DOL foreign labor disclosure data.

Attention: Wikipedia attention spike became public on 9 Sep 2025

Amgen drew 5,703 Wikipedia page views in the week of 1 Sep 2025, 1.8× the same week last year.

This period
5,703 (the week of 1 Sep 2025)
Normal week (median of 26 earlier)
2,887
Typical spread (median absolute deviation)
203
How far from its usual level
+9.4
Same week last year
3,140
History used
2,441 days
2025-03-03: 3,8392025-03-10: 4,0492025-03-17: 2,9122025-03-24: 2,9042025-03-31: 3,1462025-04-07: 3,5092025-04-14: 2,8802025-04-21: 2,8942025-04-28: 2,9272025-05-05: 2,8962025-05-12: 2,9042025-05-19: 2,6812025-05-26: 2,4032025-06-02: 2,5312025-06-09: 2,5732025-06-16: 2,4042025-06-23: 2,6872025-06-30: 2,0612025-07-07: 2,4552025-07-14: 2,5332025-07-21: 2,8262025-07-28: 3,0402025-08-04: 2,7902025-08-11: 2,9732025-08-18: 2,9312025-08-25: 2,3732025-09-01: 5,703
the week of 1 Sep 202526 earlier weeksnormal: 2,887

Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

Check it at the source: Wikimedia page view statistics.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

6 May 2025confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Amgen (AMGN): had 14.5M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year, while it spent $411.0M on capital projects in the quarter ended 31 Mar 2025, 1.8× the same quarter last year. Two unrelated kinds of activity within 28 days.

  • Short interest and volume: Short interest spike, became public on 10 Apr 2025
  • Short interest and volume: Short interest spike, became public on 26 Apr 2025
  • Financials: Quarterly capital spending jump, became public on 6 May 2025
  • Short interest and volume: Short interest spike, became public on 10 May 2025
2024-04-15: 10.1M2024-04-30: 9.7M2024-05-15: 10.2M2024-05-31: 9.0M2024-06-14: 9.1M2024-06-28: 9.0M2024-07-15: 9.6M2024-07-31: 9.8M2024-08-15: 9.2M2024-08-30: 8.5M2024-09-13: 9.0M2024-09-30: 9.8M2024-10-15: 9.4M2024-10-31: 8.8M2024-11-15: 9.8M2024-11-29: 11.1M2024-12-13: 11.5M2024-12-31: 11.2M2025-01-15: 11.4M2025-01-31: 12.7M2025-02-14: 16.1M2025-02-28: 16.2M2025-03-14: 15.1M2025-03-31: 14.1M2025-04-15: 14.5M
The 15 Apr 2025 report against the 24 reports before it. this reportearliernormal: 9.8M
See the evidence (4 changes)

Short interest and volume: Short interest spike became public on 10 Apr 2025

Amgen had 14.1M shares sold short in the 31 Mar 2025 report, 1.3× the same report last year.

This period
14.1M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
787K
How far from its usual level
+3.7
Same report last year
10.5M
History used
2,649 days
2024-03-28: 10.5M2024-04-15: 10.1M2024-04-30: 9.7M2024-05-15: 10.2M2024-05-31: 9.0M2024-06-14: 9.1M2024-06-28: 9.0M2024-07-15: 9.6M2024-07-31: 9.8M2024-08-15: 9.2M2024-08-30: 8.5M2024-09-13: 9.0M2024-09-30: 9.8M2024-10-15: 9.4M2024-10-31: 8.8M2024-11-15: 9.8M2024-11-29: 11.1M2024-12-13: 11.5M2024-12-31: 11.2M2025-01-15: 11.4M2025-01-31: 12.7M2025-02-14: 16.1M2025-02-28: 16.2M2025-03-14: 15.1M2025-03-31: 14.1M
the 31 Mar 2025 report24 earlier reportsnormal: 9.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Apr 2025

Amgen had 14.5M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.

This period
14.5M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
819K
How far from its usual level
+3.9
Same report last year
10.1M
History used
2,664 days
2024-04-15: 10.1M2024-04-30: 9.7M2024-05-15: 10.2M2024-05-31: 9.0M2024-06-14: 9.1M2024-06-28: 9.0M2024-07-15: 9.6M2024-07-31: 9.8M2024-08-15: 9.2M2024-08-30: 8.5M2024-09-13: 9.0M2024-09-30: 9.8M2024-10-15: 9.4M2024-10-31: 8.8M2024-11-15: 9.8M2024-11-29: 11.1M2024-12-13: 11.5M2024-12-31: 11.2M2025-01-15: 11.4M2025-01-31: 12.7M2025-02-14: 16.1M2025-02-28: 16.2M2025-03-14: 15.1M2025-03-31: 14.1M2025-04-15: 14.5M
the 15 Apr 2025 report24 earlier reportsnormal: 9.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly capital spending jump became public on 6 May 2025

Amgen spent $411.0M on capital projects in the quarter ended 31 Mar 2025, 1.8× the same quarter last year.

This period
$411.0M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$253.0M
Typical spread (median absolute deviation)
$16.5M
How far from its usual level
+6.2
Same quarter last year
$230.0M
History used
5,934 days
2023-03-31: $344.0M2023-06-30: $271.0M2023-09-30: $248.0M2023-12-31: $249.0M2024-03-31: $230.0M2024-06-30: $238.0M2024-09-30: $257.0M2024-12-31: $371.0M2025-03-31: $411.0M
the quarter ended 31 Mar 20258 earlier quartersnormal: $253.0M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 10 May 2025

Amgen had 14.6M shares sold short in the 30 Apr 2025 report, 1.5× the same report last year.

This period
14.6M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
906K
How far from its usual level
+3.6
Same report last year
9.7M
History used
2,679 days
2024-04-30: 9.7M2024-05-15: 10.2M2024-05-31: 9.0M2024-06-14: 9.1M2024-06-28: 9.0M2024-07-15: 9.6M2024-07-31: 9.8M2024-08-15: 9.2M2024-08-30: 8.5M2024-09-13: 9.0M2024-09-30: 9.8M2024-10-15: 9.4M2024-10-31: 8.8M2024-11-15: 9.8M2024-11-29: 11.1M2024-12-13: 11.5M2024-12-31: 11.2M2025-01-15: 11.4M2025-01-31: 12.7M2025-02-14: 16.1M2025-02-28: 16.2M2025-03-14: 15.1M2025-03-31: 14.1M2025-04-15: 14.5M2025-04-30: 14.6M
the 30 Apr 2025 report24 earlier reportsnormal: 9.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

15 Mar 2022confirmed

Confirmed across sources Hiring and Filings + Financials and Short interest and volume

Amgen (AMGN): spent $287.0M on capital projects in the quarter ended 31 Dec 2021, 1.7× the same quarter last year; it also had 28 H-1B/E-3 visa applications certified in November 2021, 3.1× the same month last year; and it had 20.7M shares sold short in the 14 Apr 2022 report, 1.9× the same report last year. Three unrelated kinds of activity within 126 days.

  • Financials: Quarterly capital spending jump, became public on 22 Feb 2022
  • Short interest and volume: Short interest spike, became public on 10 Mar 2022
  • Short interest and volume: Short interest spike, became public on 25 Mar 2022
  • Hiring: H-1B/E-3 applications change, became public on 31 Mar 2022
  • Short interest and volume: Short interest spike, became public on 12 Apr 2022
  • Short interest and volume: Short interest spike, became public on 27 Apr 2022
  • Short interest and volume: Short interest spike, became public on 11 May 2022
  • Short interest and volume: Short interest spike, became public on 25 May 2022
  • Short interest and volume: Short interest spike, became public on 10 Jun 2022
  • Short interest and volume: Short interest spike, became public on 28 Jun 2022
2019-12-31: $188.0M2020-03-31: $142.0M2020-06-30: $158.0M2020-09-30: $135.0M2020-12-31: $173.0M2021-03-31: $166.0M2021-06-30: $185.0M2021-09-30: $242.0M2021-12-31: $287.0M
The quarter ended 31 Dec 2021 against the 8 quarters before it. this quarterearliernormal: $169.5M
See the evidence (10 changes)

Financials: Quarterly capital spending jump became public on 22 Feb 2022

Amgen spent $287.0M on capital projects in the quarter ended 31 Dec 2021, 1.7× the same quarter last year.

This period
$287.0M (the quarter ended 31 Dec 2021)
Normal quarter (median of 8 earlier)
$169.5M
Typical spread (median absolute deviation)
$17.0M
How far from its usual level
+4.7
Same quarter last year
$173.0M
History used
4,748 days
2019-12-31: $188.0M2020-03-31: $142.0M2020-06-30: $158.0M2020-09-30: $135.0M2020-12-31: $173.0M2021-03-31: $166.0M2021-06-30: $185.0M2021-09-30: $242.0M2021-12-31: $287.0M
the quarter ended 31 Dec 20218 earlier quartersnormal: $169.5M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 10 Mar 2022

Amgen had 26.6M shares sold short in the 28 Feb 2022 report, 3.3× the same report last year.

This period
26.6M (the 28 Feb 2022 report)
Normal report (median of 24 earlier)
11.2M
Typical spread (median absolute deviation)
526K
How far from its usual level
+13.7
Same report last year
8.1M
History used
1,522 days
2021-02-12: 8.7M2021-02-26: 8.1M2021-03-15: 9.9M2021-03-31: 11.4M2021-04-15: 11.0M2021-04-30: 10.6M2021-05-14: 11.5M2021-05-28: 10.0M2021-06-15: 10.0M2021-06-30: 9.3M2021-07-15: 10.3M2021-07-30: 10.7M2021-08-13: 11.2M2021-08-31: 11.2M2021-09-15: 11.6M2021-09-30: 11.1M2021-10-15: 11.4M2021-10-29: 11.8M2021-11-15: 11.6M2021-11-30: 12.9M2021-12-15: 11.4M2022-01-14: 11.8M2022-01-31: 11.6M2022-02-15: 11.9M2022-02-28: 26.6M
the 28 Feb 2022 report24 earlier reportsnormal: 11.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Mar 2022

Amgen had 24.5M shares sold short in the 15 Mar 2022 report, 2.5× the same report last year.

This period
24.5M (the 15 Mar 2022 report)
Normal report (median of 24 earlier)
11.3M
Typical spread (median absolute deviation)
470K
How far from its usual level
+11.6
Same report last year
9.9M
History used
1,537 days
2021-02-26: 8.1M2021-03-15: 9.9M2021-03-31: 11.4M2021-04-15: 11.0M2021-04-30: 10.6M2021-05-14: 11.5M2021-05-28: 10.0M2021-06-15: 10.0M2021-06-30: 9.3M2021-07-15: 10.3M2021-07-30: 10.7M2021-08-13: 11.2M2021-08-31: 11.2M2021-09-15: 11.6M2021-09-30: 11.1M2021-10-15: 11.4M2021-10-29: 11.8M2021-11-15: 11.6M2021-11-30: 12.9M2021-12-15: 11.4M2022-01-14: 11.8M2022-01-31: 11.6M2022-02-15: 11.9M2022-02-28: 26.6M2022-03-15: 24.5M
the 15 Mar 2022 report24 earlier reportsnormal: 11.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Hiring: H-1B/E-3 applications change became public on 31 Mar 2022

Amgen had 28 H-1B/E-3 visa applications certified in November 2021, 3.1× the same month last year.

This period
28 (November 2021)
Normal month (median of 2 earlier)
11
Typical spread (median absolute deviation)
2
How far from its usual level
+5.7
Same month last year
9
History used
791 days
2019-11-01: 132020-11-01: 92021-11-01: 28
November 20212 earlier monthsnormal: 11

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

Check it at the source: DOL foreign labor disclosure data.

Short interest and volume: Short interest spike became public on 12 Apr 2022

Amgen had 22.5M shares sold short in the 31 Mar 2022 report, 2.0× the same report last year.

This period
22.5M (the 31 Mar 2022 report)
Normal report (median of 24 earlier)
11.4M
Typical spread (median absolute deviation)
414K
How far from its usual level
+9.8
Same report last year
11.4M
History used
1,553 days
2021-03-15: 9.9M2021-03-31: 11.4M2021-04-15: 11.0M2021-04-30: 10.6M2021-05-14: 11.5M2021-05-28: 10.0M2021-06-15: 10.0M2021-06-30: 9.3M2021-07-15: 10.3M2021-07-30: 10.7M2021-08-13: 11.2M2021-08-31: 11.2M2021-09-15: 11.6M2021-09-30: 11.1M2021-10-15: 11.4M2021-10-29: 11.8M2021-11-15: 11.6M2021-11-30: 12.9M2021-12-15: 11.4M2022-01-14: 11.8M2022-01-31: 11.6M2022-02-15: 11.9M2022-02-28: 26.6M2022-03-15: 24.5M2022-03-31: 22.5M
the 31 Mar 2022 report24 earlier reportsnormal: 11.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Apr 2022

Amgen had 20.7M shares sold short in the 14 Apr 2022 report, 1.9× the same report last year.

This period
20.7M (the 14 Apr 2022 report)
Normal report (median of 24 earlier)
11.4M
Typical spread (median absolute deviation)
414K
How far from its usual level
+8.2
Same report last year
11.0M
History used
1,567 days
2021-03-31: 11.4M2021-04-15: 11.0M2021-04-30: 10.6M2021-05-14: 11.5M2021-05-28: 10.0M2021-06-15: 10.0M2021-06-30: 9.3M2021-07-15: 10.3M2021-07-30: 10.7M2021-08-13: 11.2M2021-08-31: 11.2M2021-09-15: 11.6M2021-09-30: 11.1M2021-10-15: 11.4M2021-10-29: 11.8M2021-11-15: 11.6M2021-11-30: 12.9M2021-12-15: 11.4M2022-01-14: 11.8M2022-01-31: 11.6M2022-02-15: 11.9M2022-02-28: 26.6M2022-03-15: 24.5M2022-03-31: 22.5M2022-04-14: 20.7M
the 14 Apr 2022 report24 earlier reportsnormal: 11.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 May 2022

Amgen had 19.9M shares sold short in the 29 Apr 2022 report, 1.9× the same report last year.

This period
19.9M (the 29 Apr 2022 report)
Normal report (median of 24 earlier)
11.4M
Typical spread (median absolute deviation)
457K
How far from its usual level
+7.4
Same report last year
10.6M
History used
1,582 days
2021-04-15: 11.0M2021-04-30: 10.6M2021-05-14: 11.5M2021-05-28: 10.0M2021-06-15: 10.0M2021-06-30: 9.3M2021-07-15: 10.3M2021-07-30: 10.7M2021-08-13: 11.2M2021-08-31: 11.2M2021-09-15: 11.6M2021-09-30: 11.1M2021-10-15: 11.4M2021-10-29: 11.8M2021-11-15: 11.6M2021-11-30: 12.9M2021-12-15: 11.4M2022-01-14: 11.8M2022-01-31: 11.6M2022-02-15: 11.9M2022-02-28: 26.6M2022-03-15: 24.5M2022-03-31: 22.5M2022-04-14: 20.7M2022-04-29: 19.9M
the 29 Apr 2022 report24 earlier reportsnormal: 11.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 May 2022

Amgen had 18.9M shares sold short in the 13 May 2022 report, 1.6× the same report last year.

This period
18.9M (the 13 May 2022 report)
Normal report (median of 24 earlier)
11.5M
Typical spread (median absolute deviation)
620K
How far from its usual level
+6.4
Same report last year
11.5M
History used
1,596 days
2021-04-30: 10.6M2021-05-14: 11.5M2021-05-28: 10.0M2021-06-15: 10.0M2021-06-30: 9.3M2021-07-15: 10.3M2021-07-30: 10.7M2021-08-13: 11.2M2021-08-31: 11.2M2021-09-15: 11.6M2021-09-30: 11.1M2021-10-15: 11.4M2021-10-29: 11.8M2021-11-15: 11.6M2021-11-30: 12.9M2021-12-15: 11.4M2022-01-14: 11.8M2022-01-31: 11.6M2022-02-15: 11.9M2022-02-28: 26.6M2022-03-15: 24.5M2022-03-31: 22.5M2022-04-14: 20.7M2022-04-29: 19.9M2022-05-13: 18.9M
the 13 May 2022 report24 earlier reportsnormal: 11.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Jun 2022

Amgen had 20.3M shares sold short in the 31 May 2022 report, 2.0× the same report last year.

This period
20.3M (the 31 May 2022 report)
Normal report (median of 24 earlier)
11.6M
Typical spread (median absolute deviation)
702K
How far from its usual level
+7.5
Same report last year
10.0M
History used
1,614 days
2021-05-14: 11.5M2021-05-28: 10.0M2021-06-15: 10.0M2021-06-30: 9.3M2021-07-15: 10.3M2021-07-30: 10.7M2021-08-13: 11.2M2021-08-31: 11.2M2021-09-15: 11.6M2021-09-30: 11.1M2021-10-15: 11.4M2021-10-29: 11.8M2021-11-15: 11.6M2021-11-30: 12.9M2021-12-15: 11.4M2022-01-14: 11.8M2022-01-31: 11.6M2022-02-15: 11.9M2022-02-28: 26.6M2022-03-15: 24.5M2022-03-31: 22.5M2022-04-14: 20.7M2022-04-29: 19.9M2022-05-13: 18.9M2022-05-31: 20.3M
the 31 May 2022 report24 earlier reportsnormal: 11.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Jun 2022

Amgen had 18.5M shares sold short in the 15 Jun 2022 report, 1.8× the same report last year.

This period
18.5M (the 15 Jun 2022 report)
Normal report (median of 24 earlier)
11.6M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+4.2
Same report last year
10.0M
History used
1,629 days
2021-05-28: 10.0M2021-06-15: 10.0M2021-06-30: 9.3M2021-07-15: 10.3M2021-07-30: 10.7M2021-08-13: 11.2M2021-08-31: 11.2M2021-09-15: 11.6M2021-09-30: 11.1M2021-10-15: 11.4M2021-10-29: 11.8M2021-11-15: 11.6M2021-11-30: 12.9M2021-12-15: 11.4M2022-01-14: 11.8M2022-01-31: 11.6M2022-02-15: 11.9M2022-02-28: 26.6M2022-03-15: 24.5M2022-03-31: 22.5M2022-04-14: 20.7M2022-04-29: 19.9M2022-05-13: 18.9M2022-05-31: 20.3M2022-06-15: 18.5M
the 15 Jun 2022 report24 earlier reportsnormal: 11.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 26 Oct 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 26 Oct 2026Filings record

    Director or officer change

  3. 8 Oct 2026Lobbying record

    AMGEN: new lobbying registration (BRAVO STRATEGY GROUP) (dated 1 Jul 2026)

  4. 31 Jul 2026Filings record

    Material cybersecurity incident

  5. 12 Jun 2026Lobbying record

    AMGEN INC.: lobbying engagement terminated (WASHINGTON ADVOCACY GROUP)

  6. 12 Jun 2026Lobbying record

    AMGEN INC.: new lobbying registration (MICHAEL J. LAMOUREUX)

  7. 1 Jun 2026Lobbying record

    AMGEN, INC.: new lobbying registration (AVENUE SOLUTIONS) (dated 1 Apr 2026)

  8. 19 May 2026Filings record

    Director or officer change

  9. 22 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 22 Apr 2026Filings record

    Director or officer change

  11. 11 Apr 2026Lobbying record

    AMGEN, INC.: lobbying engagement terminated (TIBER CREEK HEALTH STRATEGIES, INC.) (dated 1 Jan 2026)

  12. 17 Feb 2026Financials change

    spent $642.0M on capital projects in the quarter ended 31 Dec 2025, 1.7× the same quarter last year.

    Same quarter last year: $371.0M; its normal quarter is $313.0M.

    See the evidence
    This period
    $642.0M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $313.0M
    Typical spread (median absolute deviation)
    $69.5M
    How far from its usual level
    +3.2
    Same quarter last year
    $371.0M
    History used
    6,209 days
    2023-12-31: $249.0M2024-03-31: $230.0M2024-06-30: $238.0M2024-09-30: $257.0M2024-12-31: $371.0M2025-03-31: $411.0M2025-06-30: $369.0M2025-09-30: $436.0M2025-12-31: $642.0M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $313.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  13. 30 Jan 2026Filings record

    A major agreement ended

  14. 17 Nov 2025Lobbying record

    AMGEN: new lobbying registration (SIGHTLINE ADVOCACY, LLC) (dated 1 Oct 2025)

  15. 6 Nov 2025Financials change

    spent $436.0M on capital projects in the quarter ended 30 Sep 2025, 1.7× the same quarter last year.

    Same quarter last year: $257.0M; its normal quarter is $253.0M.

    See the evidence
    This period
    $436.0M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $253.0M
    Typical spread (median absolute deviation)
    $19.0M
    How far from its usual level
    +6.5
    Same quarter last year
    $257.0M
    History used
    3,470 days
    2023-09-30: $248.0M2023-12-31: $249.0M2024-03-31: $230.0M2024-06-30: $238.0M2024-09-30: $257.0M2024-12-31: $371.0M2025-03-31: $411.0M2025-06-30: $369.0M2025-09-30: $436.0M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $253.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  16. 9 Sep 2025Attention change

    drew 5,703 Wikipedia page views in the week of 1 Sep 2025, 1.8× the same week last year.

    Same week last year: 3,140; its normal week is 2,887.

    See the evidence
    This period
    5,703 (the week of 1 Sep 2025)
    Normal week (median of 26 earlier)
    2,887
    Typical spread (median absolute deviation)
    203
    How far from its usual level
    +9.4
    Same week last year
    3,140
    History used
    2,441 days
    2025-03-03: 3,8392025-03-10: 4,0492025-03-17: 2,9122025-03-24: 2,9042025-03-31: 3,1462025-04-07: 3,5092025-04-14: 2,8802025-04-21: 2,8942025-04-28: 2,9272025-05-05: 2,8962025-05-12: 2,9042025-05-19: 2,6812025-05-26: 2,4032025-06-02: 2,5312025-06-09: 2,5732025-06-16: 2,4042025-06-23: 2,6872025-06-30: 2,0612025-07-07: 2,4552025-07-14: 2,5332025-07-21: 2,8262025-07-28: 3,0402025-08-04: 2,7902025-08-11: 2,9732025-08-18: 2,9312025-08-25: 2,3732025-09-01: 5,703
    the week of 1 Sep 202526 earlier weeksnormal: 2,887

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  17. 2 Sep 2025several at once

    spent $369.0M on capital projects in the quarter ended 30 Jun 2025, 1.6× the same quarter last year; it also had 47 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year; and it drew 5,703 Wikipedia page views in the week of 1 Sep 2025, 1.8× the same week last year. Three unrelated kinds of activity within 33 days.

    See the evidence (3 changes)

    Financials: Quarterly capital spending jump became public on 7 Aug 2025

    Amgen spent $369.0M on capital projects in the quarter ended 30 Jun 2025, 1.6× the same quarter last year.

    This period
    $369.0M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $253.0M
    Typical spread (median absolute deviation)
    $16.5M
    How far from its usual level
    +4.6
    Same quarter last year
    $238.0M
    History used
    3,378 days
    2023-06-30: $271.0M2023-09-30: $248.0M2023-12-31: $249.0M2024-03-31: $230.0M2024-06-30: $238.0M2024-09-30: $257.0M2024-12-31: $371.0M2025-03-31: $411.0M2025-06-30: $369.0M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $253.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Hiring: H-1B/E-3 applications change became public on 31 Aug 2025

    Amgen had 47 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year.

    This period
    47 (June 2025)
    Normal month (median of 5 earlier)
    20
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +9.0
    Same month last year
    22
    History used
    2,099 days
    2020-06-01: 72021-06-01: 252022-06-01: 192023-06-01: 202024-06-01: 222025-06-01: 47
    June 20255 earlier monthsnormal: 20

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

    Check it at the source: DOL foreign labor disclosure data.

    Attention: Wikipedia attention spike became public on 9 Sep 2025

    Amgen drew 5,703 Wikipedia page views in the week of 1 Sep 2025, 1.8× the same week last year.

    This period
    5,703 (the week of 1 Sep 2025)
    Normal week (median of 26 earlier)
    2,887
    Typical spread (median absolute deviation)
    203
    How far from its usual level
    +9.4
    Same week last year
    3,140
    History used
    2,441 days
    2025-03-03: 3,8392025-03-10: 4,0492025-03-17: 2,9122025-03-24: 2,9042025-03-31: 3,1462025-04-07: 3,5092025-04-14: 2,8802025-04-21: 2,8942025-04-28: 2,9272025-05-05: 2,8962025-05-12: 2,9042025-05-19: 2,6812025-05-26: 2,4032025-06-02: 2,5312025-06-09: 2,5732025-06-16: 2,4042025-06-23: 2,6872025-06-30: 2,0612025-07-07: 2,4552025-07-14: 2,5332025-07-21: 2,8262025-07-28: 3,0402025-08-04: 2,7902025-08-11: 2,9732025-08-18: 2,9312025-08-25: 2,3732025-09-01: 5,703
    the week of 1 Sep 202526 earlier weeksnormal: 2,887

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  18. 31 Aug 2025Hiring change

    had 47 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year.

    Same month last year: 22; its normal month is 20.

    See the evidence
    This period
    47 (June 2025)
    Normal month (median of 5 earlier)
    20
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +9.0
    Same month last year
    22
    History used
    2,099 days
    2020-06-01: 72021-06-01: 252022-06-01: 192023-06-01: 202024-06-01: 222025-06-01: 47
    June 20255 earlier monthsnormal: 20

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

    Check it at the source: DOL foreign labor disclosure data.

  19. 7 Aug 2025Financials change

    spent $369.0M on capital projects in the quarter ended 30 Jun 2025, 1.6× the same quarter last year.

    Same quarter last year: $238.0M; its normal quarter is $253.0M.

    See the evidence
    This period
    $369.0M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $253.0M
    Typical spread (median absolute deviation)
    $16.5M
    How far from its usual level
    +4.6
    Same quarter last year
    $238.0M
    History used
    3,378 days
    2023-06-30: $271.0M2023-09-30: $248.0M2023-12-31: $249.0M2024-03-31: $230.0M2024-06-30: $238.0M2024-09-30: $257.0M2024-12-31: $371.0M2025-03-31: $411.0M2025-06-30: $369.0M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $253.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  20. 15 Jul 2025Lobbying record

    TIBER CREEK HEALTH STRATEGIES, INC. ON BEHALF OF AMGEN, INC.: new lobbying registration (B HALL STRATEGIES, LLC) (dated 1 Apr 2025)

  21. 10 May 2025Short interest and volume change

    had 14.6M shares sold short in the 30 Apr 2025 report, 1.5× the same report last year.

    Same report last year: 9.7M; its normal report is 9.8M.

    See the evidence
    This period
    14.6M (the 30 Apr 2025 report)
    Normal report (median of 24 earlier)
    9.8M
    Typical spread (median absolute deviation)
    906K
    How far from its usual level
    +3.6
    Same report last year
    9.7M
    History used
    2,679 days
    2024-04-30: 9.7M2024-05-15: 10.2M2024-05-31: 9.0M2024-06-14: 9.1M2024-06-28: 9.0M2024-07-15: 9.6M2024-07-31: 9.8M2024-08-15: 9.2M2024-08-30: 8.5M2024-09-13: 9.0M2024-09-30: 9.8M2024-10-15: 9.4M2024-10-31: 8.8M2024-11-15: 9.8M2024-11-29: 11.1M2024-12-13: 11.5M2024-12-31: 11.2M2025-01-15: 11.4M2025-01-31: 12.7M2025-02-14: 16.1M2025-02-28: 16.2M2025-03-14: 15.1M2025-03-31: 14.1M2025-04-15: 14.5M2025-04-30: 14.6M
    the 30 Apr 2025 report24 earlier reportsnormal: 9.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 7 May 2025Lobbying record

    AMGEN: new lobbying registration (DAN CRIPPEN) (dated 1 May 2025)

  23. 6 May 2025several at once

    had 14.5M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year, while it spent $411.0M on capital projects in the quarter ended 31 Mar 2025, 1.8× the same quarter last year. Two unrelated kinds of activity within 28 days.

    See the evidence (4 changes)

    Short interest and volume: Short interest spike became public on 10 Apr 2025

    Amgen had 14.1M shares sold short in the 31 Mar 2025 report, 1.3× the same report last year.

    This period
    14.1M (the 31 Mar 2025 report)
    Normal report (median of 24 earlier)
    9.8M
    Typical spread (median absolute deviation)
    787K
    How far from its usual level
    +3.7
    Same report last year
    10.5M
    History used
    2,649 days
    2024-03-28: 10.5M2024-04-15: 10.1M2024-04-30: 9.7M2024-05-15: 10.2M2024-05-31: 9.0M2024-06-14: 9.1M2024-06-28: 9.0M2024-07-15: 9.6M2024-07-31: 9.8M2024-08-15: 9.2M2024-08-30: 8.5M2024-09-13: 9.0M2024-09-30: 9.8M2024-10-15: 9.4M2024-10-31: 8.8M2024-11-15: 9.8M2024-11-29: 11.1M2024-12-13: 11.5M2024-12-31: 11.2M2025-01-15: 11.4M2025-01-31: 12.7M2025-02-14: 16.1M2025-02-28: 16.2M2025-03-14: 15.1M2025-03-31: 14.1M
    the 31 Mar 2025 report24 earlier reportsnormal: 9.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Apr 2025

    Amgen had 14.5M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.

    This period
    14.5M (the 15 Apr 2025 report)
    Normal report (median of 24 earlier)
    9.8M
    Typical spread (median absolute deviation)
    819K
    How far from its usual level
    +3.9
    Same report last year
    10.1M
    History used
    2,664 days
    2024-04-15: 10.1M2024-04-30: 9.7M2024-05-15: 10.2M2024-05-31: 9.0M2024-06-14: 9.1M2024-06-28: 9.0M2024-07-15: 9.6M2024-07-31: 9.8M2024-08-15: 9.2M2024-08-30: 8.5M2024-09-13: 9.0M2024-09-30: 9.8M2024-10-15: 9.4M2024-10-31: 8.8M2024-11-15: 9.8M2024-11-29: 11.1M2024-12-13: 11.5M2024-12-31: 11.2M2025-01-15: 11.4M2025-01-31: 12.7M2025-02-14: 16.1M2025-02-28: 16.2M2025-03-14: 15.1M2025-03-31: 14.1M2025-04-15: 14.5M
    the 15 Apr 2025 report24 earlier reportsnormal: 9.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly capital spending jump became public on 6 May 2025

    Amgen spent $411.0M on capital projects in the quarter ended 31 Mar 2025, 1.8× the same quarter last year.

    This period
    $411.0M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $253.0M
    Typical spread (median absolute deviation)
    $16.5M
    How far from its usual level
    +6.2
    Same quarter last year
    $230.0M
    History used
    5,934 days
    2023-03-31: $344.0M2023-06-30: $271.0M2023-09-30: $248.0M2023-12-31: $249.0M2024-03-31: $230.0M2024-06-30: $238.0M2024-09-30: $257.0M2024-12-31: $371.0M2025-03-31: $411.0M
    the quarter ended 31 Mar 20258 earlier quartersnormal: $253.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 10 May 2025

    Amgen had 14.6M shares sold short in the 30 Apr 2025 report, 1.5× the same report last year.

    This period
    14.6M (the 30 Apr 2025 report)
    Normal report (median of 24 earlier)
    9.8M
    Typical spread (median absolute deviation)
    906K
    How far from its usual level
    +3.6
    Same report last year
    9.7M
    History used
    2,679 days
    2024-04-30: 9.7M2024-05-15: 10.2M2024-05-31: 9.0M2024-06-14: 9.1M2024-06-28: 9.0M2024-07-15: 9.6M2024-07-31: 9.8M2024-08-15: 9.2M2024-08-30: 8.5M2024-09-13: 9.0M2024-09-30: 9.8M2024-10-15: 9.4M2024-10-31: 8.8M2024-11-15: 9.8M2024-11-29: 11.1M2024-12-13: 11.5M2024-12-31: 11.2M2025-01-15: 11.4M2025-01-31: 12.7M2025-02-14: 16.1M2025-02-28: 16.2M2025-03-14: 15.1M2025-03-31: 14.1M2025-04-15: 14.5M2025-04-30: 14.6M
    the 30 Apr 2025 report24 earlier reportsnormal: 9.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  24. 6 May 2025Financials change

    spent $411.0M on capital projects in the quarter ended 31 Mar 2025, 1.8× the same quarter last year.

    Same quarter last year: $230.0M; its normal quarter is $253.0M.

    See the evidence
    This period
    $411.0M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $253.0M
    Typical spread (median absolute deviation)
    $16.5M
    How far from its usual level
    +6.2
    Same quarter last year
    $230.0M
    History used
    5,934 days
    2023-03-31: $344.0M2023-06-30: $271.0M2023-09-30: $248.0M2023-12-31: $249.0M2024-03-31: $230.0M2024-06-30: $238.0M2024-09-30: $257.0M2024-12-31: $371.0M2025-03-31: $411.0M
    the quarter ended 31 Mar 20258 earlier quartersnormal: $253.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  25. 26 Apr 2025Short interest and volume change

    had 14.5M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.

    Same report last year: 10.1M; its normal report is 9.8M.

    See the evidence
    This period
    14.5M (the 15 Apr 2025 report)
    Normal report (median of 24 earlier)
    9.8M
    Typical spread (median absolute deviation)
    819K
    How far from its usual level
    +3.9
    Same report last year
    10.1M
    History used
    2,664 days
    2024-04-15: 10.1M2024-04-30: 9.7M2024-05-15: 10.2M2024-05-31: 9.0M2024-06-14: 9.1M2024-06-28: 9.0M2024-07-15: 9.6M2024-07-31: 9.8M2024-08-15: 9.2M2024-08-30: 8.5M2024-09-13: 9.0M2024-09-30: 9.8M2024-10-15: 9.4M2024-10-31: 8.8M2024-11-15: 9.8M2024-11-29: 11.1M2024-12-13: 11.5M2024-12-31: 11.2M2025-01-15: 11.4M2025-01-31: 12.7M2025-02-14: 16.1M2025-02-28: 16.2M2025-03-14: 15.1M2025-03-31: 14.1M2025-04-15: 14.5M
    the 15 Apr 2025 report24 earlier reportsnormal: 9.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 11 Apr 2025Lobbying record

    AMGEN: new lobbying registration (CAPITOL 6 ADVISORS) (dated 4 Apr 2025)

  27. 10 Apr 2025Short interest and volume change

    had 14.1M shares sold short in the 31 Mar 2025 report, 1.3× the same report last year.

    Same report last year: 10.5M; its normal report is 9.8M.

    See the evidence
    This period
    14.1M (the 31 Mar 2025 report)
    Normal report (median of 24 earlier)
    9.8M
    Typical spread (median absolute deviation)
    787K
    How far from its usual level
    +3.7
    Same report last year
    10.5M
    History used
    2,649 days
    2024-03-28: 10.5M2024-04-15: 10.1M2024-04-30: 9.7M2024-05-15: 10.2M2024-05-31: 9.0M2024-06-14: 9.1M2024-06-28: 9.0M2024-07-15: 9.6M2024-07-31: 9.8M2024-08-15: 9.2M2024-08-30: 8.5M2024-09-13: 9.0M2024-09-30: 9.8M2024-10-15: 9.4M2024-10-31: 8.8M2024-11-15: 9.8M2024-11-29: 11.1M2024-12-13: 11.5M2024-12-31: 11.2M2025-01-15: 11.4M2025-01-31: 12.7M2025-02-14: 16.1M2025-02-28: 16.2M2025-03-14: 15.1M2025-03-31: 14.1M
    the 31 Mar 2025 report24 earlier reportsnormal: 9.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 26 Mar 2025Short interest and volume change

    had 15.1M shares sold short in the 14 Mar 2025 report, 1.4× the same report last year.

    Same report last year: 11.1M; its normal report is 9.8M.

    See the evidence
    This period
    15.1M (the 14 Mar 2025 report)
    Normal report (median of 24 earlier)
    9.8M
    Typical spread (median absolute deviation)
    787K
    How far from its usual level
    +4.5
    Same report last year
    11.1M
    History used
    2,632 days
    2024-03-15: 11.1M2024-03-28: 10.5M2024-04-15: 10.1M2024-04-30: 9.7M2024-05-15: 10.2M2024-05-31: 9.0M2024-06-14: 9.1M2024-06-28: 9.0M2024-07-15: 9.6M2024-07-31: 9.8M2024-08-15: 9.2M2024-08-30: 8.5M2024-09-13: 9.0M2024-09-30: 9.8M2024-10-15: 9.4M2024-10-31: 8.8M2024-11-15: 9.8M2024-11-29: 11.1M2024-12-13: 11.5M2024-12-31: 11.2M2025-01-15: 11.4M2025-01-31: 12.7M2025-02-14: 16.1M2025-02-28: 16.2M2025-03-14: 15.1M
    the 14 Mar 2025 report24 earlier reportsnormal: 9.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 12 Mar 2025Short interest and volume change

    had 16.2M shares sold short in the 28 Feb 2025 report, 1.5× the same report last year.

    Same report last year: 11.0M; its normal report is 9.8M.

    See the evidence
    This period
    16.2M (the 28 Feb 2025 report)
    Normal report (median of 24 earlier)
    9.8M
    Typical spread (median absolute deviation)
    787K
    How far from its usual level
    +5.4
    Same report last year
    11.0M
    History used
    2,618 days
    2024-02-29: 11.0M2024-03-15: 11.1M2024-03-28: 10.5M2024-04-15: 10.1M2024-04-30: 9.7M2024-05-15: 10.2M2024-05-31: 9.0M2024-06-14: 9.1M2024-06-28: 9.0M2024-07-15: 9.6M2024-07-31: 9.8M2024-08-15: 9.2M2024-08-30: 8.5M2024-09-13: 9.0M2024-09-30: 9.8M2024-10-15: 9.4M2024-10-31: 8.8M2024-11-15: 9.8M2024-11-29: 11.1M2024-12-13: 11.5M2024-12-31: 11.2M2025-01-15: 11.4M2025-01-31: 12.7M2025-02-14: 16.1M2025-02-28: 16.2M
    the 28 Feb 2025 report24 earlier reportsnormal: 9.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 27 Feb 2025Short interest and volume change

    had 16.1M shares sold short in the 14 Feb 2025 report, 1.4× the same report last year.

    Same report last year: 11.1M; its normal report is 9.8M.

    See the evidence
    This period
    16.1M (the 14 Feb 2025 report)
    Normal report (median of 24 earlier)
    9.8M
    Typical spread (median absolute deviation)
    787K
    How far from its usual level
    +5.4
    Same report last year
    11.1M
    History used
    2,604 days
    2024-02-15: 11.1M2024-02-29: 11.0M2024-03-15: 11.1M2024-03-28: 10.5M2024-04-15: 10.1M2024-04-30: 9.7M2024-05-15: 10.2M2024-05-31: 9.0M2024-06-14: 9.1M2024-06-28: 9.0M2024-07-15: 9.6M2024-07-31: 9.8M2024-08-15: 9.2M2024-08-30: 8.5M2024-09-13: 9.0M2024-09-30: 9.8M2024-10-15: 9.4M2024-10-31: 8.8M2024-11-15: 9.8M2024-11-29: 11.1M2024-12-13: 11.5M2024-12-31: 11.2M2025-01-15: 11.4M2025-01-31: 12.7M2025-02-14: 16.1M
    the 14 Feb 2025 report24 earlier reportsnormal: 9.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 20 Oct 2024Lobbying record

    AMGEN: lobbying engagement terminated (ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)) (dated 1 Jul 2024)

  32. 17 Sep 2024Attention change

    drew 5,235 Wikipedia page views in the week of 9 Sep 2024, 1.9× the same week last year.

    Same week last year: 2,813; its normal week is 3,127.

    See the evidence
    This period
    5,235 (the week of 9 Sep 2024)
    Normal week (median of 26 earlier)
    3,127
    Typical spread (median absolute deviation)
    159
    How far from its usual level
    +6.7
    Same week last year
    2,813
    History used
    2,084 days
    2024-03-11: 3,2632024-03-18: 3,3822024-03-25: 3,2682024-04-01: 2,9502024-04-08: 3,1992024-04-15: 3,0642024-04-22: 2,9342024-04-29: 3,8952024-05-06: 3,3212024-05-13: 3,5682024-05-20: 3,1142024-05-27: 2,9102024-06-03: 3,0172024-06-10: 2,9122024-06-17: 3,1082024-06-24: 3,0582024-07-01: 2,6982024-07-08: 3,1002024-07-15: 3,5642024-07-22: 3,2042024-07-29: 2,8832024-08-05: 3,8972024-08-12: 3,3592024-08-19: 3,2582024-08-26: 3,1082024-09-02: 3,1402024-09-09: 5,235
    the week of 9 Sep 202426 earlier weeksnormal: 3,127

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  33. 19 Jul 2024Lobbying record

    AMGEN INC.: lobbying engagement terminated (SONORAN POLICY GROUP, LLC D/B/A STRYK GLOBAL DIPLOMACY, FORMERLY KNOWN AS SONORA) (dated 30 Jun 2024)

  34. 3 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 3 Jun 2024Filings record

    Director or officer change

  36. 12 Mar 2024Short interest and volume change

    had 11.0M shares sold short in the 29 Feb 2024 report, 1.5× the same report last year.

    Same report last year: 7.4M; its normal report is 7.4M.

    See the evidence
    This period
    11.0M (the 29 Feb 2024 report)
    Normal report (median of 24 earlier)
    7.4M
    Typical spread (median absolute deviation)
    665K
    How far from its usual level
    +3.7
    Same report last year
    7.4M
    History used
    2,253 days
    2023-02-28: 7.4M2023-03-15: 7.6M2023-03-31: 7.8M2023-04-14: 8.0M2023-04-28: 7.6M2023-05-15: 7.6M2023-05-31: 7.4M2023-06-15: 7.2M2023-06-30: 7.0M2023-07-14: 7.2M2023-07-31: 6.5M2023-08-15: 7.0M2023-08-31: 6.2M2023-09-15: 6.3M2023-09-29: 6.4M2023-10-13: 6.4M2023-10-31: 6.4M2023-11-15: 6.8M2023-11-30: 8.1M2023-12-15: 9.1M2023-12-29: 9.0M2024-01-12: 8.8M2024-01-31: 9.3M2024-02-15: 11.1M2024-02-29: 11.0M
    the 29 Feb 2024 report24 earlier reportsnormal: 7.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 6 Mar 2024Lobbying record

    AMGEN INC.: new lobbying registration (WASHINGTON ADVOCACY GROUP) (dated 4 Mar 2024)

  38. 28 Feb 2024Short interest and volume change

    had 11.1M shares sold short in the 15 Feb 2024 report, 1.5× the same report last year.

    Same report last year: 7.4M; its normal report is 7.4M.

    See the evidence
    This period
    11.1M (the 15 Feb 2024 report)
    Normal report (median of 24 earlier)
    7.4M
    Typical spread (median absolute deviation)
    607K
    How far from its usual level
    +4.1
    Same report last year
    7.4M
    History used
    2,239 days
    2023-02-15: 7.4M2023-02-28: 7.4M2023-03-15: 7.6M2023-03-31: 7.8M2023-04-14: 8.0M2023-04-28: 7.6M2023-05-15: 7.6M2023-05-31: 7.4M2023-06-15: 7.2M2023-06-30: 7.0M2023-07-14: 7.2M2023-07-31: 6.5M2023-08-15: 7.0M2023-08-31: 6.2M2023-09-15: 6.3M2023-09-29: 6.4M2023-10-13: 6.4M2023-10-31: 6.4M2023-11-15: 6.8M2023-11-30: 8.1M2023-12-15: 9.1M2023-12-29: 9.0M2024-01-12: 8.8M2024-01-31: 9.3M2024-02-15: 11.1M
    the 15 Feb 2024 report24 earlier reportsnormal: 7.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 15 Feb 2024Lobbying record

    AMGEN INC.: new lobbying registration (JEFFREY J. KIMBELL & ASSOCIATES, INC.) (dated 7 Feb 2024)

  40. 13 Feb 2024Lobbying record

    AMGEN: lobbying engagement terminated (HAGGERTY POLICY SOLUTIONS) (dated 31 Dec 2023)

Showing the newest 40 of 169 entries; narrow the window or the kind of data to see older ones.

Not listed: 220 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000318154
Ticker
AMGN
Domain
amgen.com
Employer name
Amgen Incorporated (1 unverified)
Hq location
CA|THOUSAND OAKS|91320 (1 unverified)
Lobbying client
akin gump on behalf of amgen, amgen, amgen inc fka horizon therapeutics usa, capitol counsel llc on behalf of amgen and 2 more
Name
Amgen Canada Inc, Amgen (Europe) GmbH, Amgen Fremont Inc, Amgen Global Finance B.V and 35 more
Uei
D92HARF1LKA9
Wikidata
Q470517
Wikipedia
Amgen
  • DOL H-1B labor condition applications and PERM certifications1853 data points1 Oct 2019 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)198 records, 279 data points30 Dec 1899 to 30 Sep 2026
  • SEC Form 13F institutional holdings8 records, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)163 records28 Jan 2016 to 3 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1203 data points31 Dec 2006 to 29 Oct 2026
  • SEC Form 4 insider transactions82 records, 292 data points4 Mar 2016 to 13 Aug 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards7 records, 90 data points30 Sep 2009 to 2 Jun 2026
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026